Compare Recursion Pharmaceuticals Inc (RXRX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Parcel Service Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while United Parcel Service Inc trades at $99.72 (market cap $85.49B). The key difference: United Parcel Service Inc is far larger — about 46× Recursion Pharmaceuticals Inc's market cap, and United Parcel Service Inc pays a 6.53% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UPS | |
|---|---|---|
Market Cap | $1.86B | $85.49B |
Sector | Health | Industrials |
52-Week High | $6.79 | $120.00 |
52-Week Low | $2.84 | $82.58 |
Enterprise Value | $1.38B | $109.51B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
UPS trades at $100.48, down 1.78% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company maintains solid profitability with 5.08% net margin and 29.66% ROE, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent strategic moves include a $2B+ global investment initiative and executive leadership restructuring announced in August 2026.
The stock presents a mixed outlook with attractive valuation (P/E 18.68, below industry average) and strong dividend yield, but faces headwinds from declining revenue trends and competitive pressures. Analyst consensus leans neutral with $117.90 price target suggesting 17% upside potential, though execution risks on the new operating model and dividend sustainability concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
